In-silico and in-vitro study reveals ziprasidone as a potential aromatase inhibitor against breast carcinoma
Authors:
- Ankita SahuASAnkita Sahu
- Shaban AhmadShaban Ahmad
- Khalid ImtiyazKIKhalid Imtiyaz
- Ajeeshkumar Kizhakkeppurath KumaranAKAjeeshkumar Kizhakkeppurath Kumaran
- Mojahidul IslamMIMojahidul Islam
- Khalid RazaKRKhalid Raza
- Murugesh EaswaranMEMurugesh Easwaran
- Asha Kurukkan KunnathAKAsha Kurukkan Kunnath
- Moshahid A. RizviMRMoshahid A. Rizvi
- Saurabh VermaSVSaurabh Verma
Open Access
- 2 October 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-17
Abstract
Aromatase enzyme plays a fundamental role in the development of estrogen receptors, and due to this functionality, the enzyme has gained significant attention as a therapeutic for reproductive disorders and cancer diseases. The currently employed aromatase inhibitors have severe side effects whereas our novel aromatase inhibitor is more selective and less toxic, therefore has greater potential to be developed as a drug. The research framework of this study is to identify a potent inhibitor for the aromatase target by profiling molecular descriptors of the ligand and to find a functional pocket in the target by docking and MD simulations. For assessing cellular and metabolic activities as indicators of cell viability and cytotoxicity, in-vitro studies were performed by using the colorimetric MTT assay. Aromatase activities were determined by a fluorometric method. Cell morphology was assessed by phase-contrast light microscopy. Flow cytometry and Annexin V-FITC/PI staining assay determined cell cycle distribution and apoptosis. This study reports that CHEMBL708 (Ziprasidone) is the most promising compound that showed excellent aromatase inhibitory activity. By using better drug design methods and experimental studies, our study identified a novel compound that could be effective as a high-potential drug candidate against aromatase enzyme. We conclude that the compound ziprasidone effectively blocks the cell cycle at the G1-S phase and induces cancer cell death. Further, in-vivo studies are vital for developing ziprasidone as an anticancer agent. Lastly, our research outcomes based on the results of the in-silico experiments may pave the way for identifying effective drug candidates for therapeutic use in breast cancer.Keywords
All Related Versions
Funding Information
- Indian Council of Medical Research (45/17/2019-BMS/PHA)
This publication has 66 references indexed in Scilit:
- An in silico evaluation of the ADMET profile of the StreptomeDB databaseSpringerPlus, 2013
- Docking Challenge: Protein Sampling and Molecular Docking PerformanceJournal of Chemical Information and Modeling, 2013
- Evidence review and clinical guidance for the use of ziprasidone in CanadaAnnals of General Psychiatry, 2013
- The Aromatase Gene CYP19A1: Several Genetic and Functional Lines of Evidence Supporting a Role in Reading, Speech and LanguageBehavior Genetics, 2012
- ChEMBL: a large-scale bioactivity database for drug discoveryNucleic Acids Research, 2011
- Modified Annexin V/Propidium Iodide Apoptosis Assay For Accurate Assessment of Cell DeathJournal of Visualized Experiments, 2011
- X-ray structure of human aromatase reveals an androgen-specific active siteThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Molecular Dynamics: Survey of Methods for Simulating the Activity of ProteinsChemical Reviews, 2006
- Molecular dynamics simulations of biomoleculesNature Structural & Molecular Biology, 2002
- The Protein Data BankNucleic Acids Research, 2000